Abstract library

790 results for "vascular endothelial growth factor Receptor 3".
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C
#1374 The Usefulness of Assessment the Serum Concentrations of Vascular Endothelial Growth Factor (VEGF) and Its Soluble Receptor Type 2 (VEGFR2) in Patients with Neuroendocrine Neoplasm (NEN)
Introduction: Angiogenesis plays an important role in tumour growth and disease progression. VEGF is a angiogenesis-stimulating factor. VEGFR2 has antiangiogenic properties.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: MD PhD Violetta Rosiek
#2008 Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines
Introduction: Sunitinib and bevacizumab are intracellular and extracellular inhibitor of vascular endothelial growth factor(VEGF) pathway respectively, the influence of both of which on the proliferation of neuroendocrine neoplasm (NEN) cell lines in vitro was not known yet.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#2012 Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor D (VEGF-D) in tumor cells versus stroma cells in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and its clinical significance is still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#756 Evaluation of VEGF, VEGFR 1-2-3 and Endocan/ESM-1 Expression in Gastroenteropancreatic Neuroendocrine Tumors and Correlation with Ki-67 Labeling and Prognosis
Introduction: Angiogenesis is recognized to play a critical role in progressive tumor growth and spreading and its inhibition is a valuable approach to cancer treatment. Markers of angiogenesis include assessment of microvessel density on tissue sections (often evaluated with antibodies against pan-endothelial antigens, such as CD34) and expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR 1-2-3). Endocan, also called endothelial cell specific molecule-1 (ESM-1), has been shown to be expressed by endothelial tumor cells and especially by tip cells during angiogenesis. Endocan is highly up-regulated by pro-angiogenic molecules, such as VEGF. Recently, Endocan has been identified to be one of the molecules involved in the switch from dormant to fast-growing tumors. Among endocrine tumors, Endocan expression has been evaluated only in pituitary adenomas: a positive association between endothelial Endocan expression and recurrence risk, tumor size, tumoral invasion and average mitosis count has been demonstrated. In contrast, there was no association between endothelial Endocan expression and the Ki-67 labeling index
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Laura De Marinis
Authors: Lugli F, Iacovazzo D, Fusco A, Lanza P, ...
#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?
Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D, Ph.D. Apostolos Tsolakis
Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...
#304 Hepatic Neuroendocrine Tumor Metastasis Proliferation is Hepatocyte Regulated Via a 5HT7 Mediated Induction of an IGF 1 and HGF Feedback Loop Mediated by cAMP, PKA-independent pAKT and pCREB
Introduction: Carcinoid serotonin (5-HT) causes local fibrosis but the effect of 5-HT on hepatocytes has not been established. We hypothesized that tumors and hepatocytes form a metastasis-supportive environment.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Svejda B, Kidd M, Lawrence B, Alaimo D, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.